Blopress (Candesartan Cilexetil)



Indications and Reactions:

Role Indications Reactions
Secondary
Hypertension 31.1%
Ill-defined Disorder 15.1%
Cardiac Failure 13.2%
Hypercholesterolaemia 5.7%
Abdominal Distension 3.8%
Product Used For Unknown Indication 3.8%
Acromegaly 2.8%
Gout 2.8%
Atrial Fibrillation 1.9%
Convulsion 1.9%
Diabetes Mellitus 1.9%
Diabetes Mellitus Non-insulin-dependent 1.9%
Flatulence 1.9%
Hepatic Neoplasm Malignant 1.9%
Hyperlipidaemia 1.9%
Hypersensitivity 1.9%
Osteoporosis 1.9%
Pyrexia 1.9%
Type 2 Diabetes Mellitus 1.9%
Acute Tonsillitis 0.9%
Rhabdomyolysis 13.8%
Stevens-johnson Syndrome 10.3%
Interstitial Lung Disease 6.9%
Nephritis Interstitial 6.9%
Pain 6.9%
Urinary Tract Infection 6.9%
Abdominal Pain Upper 3.4%
Diverticulum Intestinal 3.4%
Drug Interaction 3.4%
Drug Toxicity 3.4%
Maternal Drugs Affecting Foetus 3.4%
Neonatal Hypoxia 3.4%
Pain In Extremity 3.4%
Pancreatic Duct Dilatation 3.4%
Postmenopausal Haemorrhage 3.4%
Presyncope 3.4%
Pruritus Generalised 3.4%
Rash 3.4%
Red Blood Cell Count Decreased 3.4%
Sinus Arrest 3.4%
Concomitant
Diabetes Mellitus 13.0%
Type 2 Diabetes Mellitus 9.7%
Rheumatoid Arthritis 9.2%
Colorectal Cancer 6.8%
Hypertension 4.8%
Hyperuricaemia 4.8%
Ill-defined Disorder 4.8%
Insomnia 4.8%
Osteoporosis 4.8%
Dementia Alzheimer's Type 4.3%
Hypertonic Bladder 4.3%
Hyperphosphataemia 3.9%
Product Used For Unknown Indication 3.9%
Cerebral Infarction 3.4%
Drug Use For Unknown Indication 3.4%
Hepatitis C 3.4%
Anxiety Disorder 2.9%
Renal Transplant 2.9%
Atrial Fibrillation 2.4%
Epilepsy 2.4%
Pyrexia 9.5%
Syncope 8.1%
Renal Impairment 6.8%
Rhabdomyolysis 6.8%
Vomiting 6.8%
Bladder Cancer 5.4%
Oedema 5.4%
White Blood Cell Count Decreased 5.4%
Bladder Transitional Cell Carcinoma 4.1%
Cerebral Infarction 4.1%
Hallucination 4.1%
Hepatic Function Abnormal 4.1%
Pituitary Tumour Benign 4.1%
Renal Failure Acute 4.1%
Respiratory Disorder 4.1%
Road Traffic Accident 4.1%
Thrombocytopenia 4.1%
Tooth Fracture 4.1%
Atrioventricular Block Third Degree 2.7%
Bladder Cancer Recurrent 2.7%